Dopaminergic therapies modulate the T-CELL proteome of patients with Parkinson's disease

IUBMB Life

Volumn 64, Issue 10, 2012, Pages 846-852

  Alberio, Tiziana ^a   Pippione, Agnese C ^a   Comi, Cristoforo ^b   Olgiati, Simone ^a   Cecconi, Daniela ^c   Zibetti, Maurizio ^d   Lopiano, Leonardo ^d   Fasano, Mauro ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^c UNIVERSITY OF VERONA   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

Author keywords

dopamine agonists; L DOPA; lymphocytes; Parkinson's disease; peroxiredoxin 6; prolidase

Indexed keywords

ACTIN RELATED PROTEIN 2; F ACTIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; LEVODOPA; PEROXIREDOXIN 6; PRAMIPEXOLE; PROLINE DIPEPTIDASE; PROTEOME; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; ROPINIROLE; ROTIGOTINE; TROPOMYOSIN;

ACTIN CAPPING; ADULT; AGED; AMINO ACID SEQUENCE; ARTICLE; CLINICAL ARTICLE; CORRELATION ANALYSIS; DOPAMINERGIC SYSTEM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MALE; MASS SPECTROMETRY; PARKINSON DISEASE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; T LYMPHOCYTE; TWO DIMENSIONAL ELECTROPHORESIS; WESTERN BLOTTING;

ADULT; AGED; BLOTTING, WESTERN; CORPUS STRIATUM; DOPAMINE; DOPAMINE AGONISTS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; GENE EXPRESSION; HUMANS; LEVODOPA; MALE; MIDDLE AGED; MITOCHONDRIAL PROTON-TRANSLOCATING ATPASES; PARKINSON DISEASE; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEOME; PROTEOMICS; T-LYMPHOCYTES;

EID: 84866664815     PISSN: 15216543     EISSN: 15216551     Source Type: Journal    
DOI: 10.1002/iub.1073     Document Type: Article

References (29)

1. Obeso, J. A., Rodriguez-Oroz, M. C., Goetz, C. G., Marin, C., Kordower, J. H., et al. (2010) Missing pieces in the Parkinson's disease puzzle. Nat. Med. 16, 653-661.
2. Shulman, J. M., De Jager, P. L., and, Feany, M. B., (2011) Parkinson's disease: genetics and pathogenesis. Annu. Rev. Pathol. 6, 193-222.
3. Rascol, O., Lozano, A., Stern, M., and, Poewe, W., (2011) Milestones in Parkinson's disease therapeutics. Mov. Disord. 26, 1072-1082.
4. Jankovic, J., and, Aguilar, L. G., (2008) Current approaches to the treatment of Parkinson's disease. Neuropsychiatr. Dis. Treat. 4, 743-757.
5. Schapira, A. H., Emre, M., Jenner, P., and, Poewe, W., (2009) Levodopa in the treatment of Parkinson's disease. Eur. J. Neurol. 16, 982-989.
6. Pacheco, R., Prado, C. E., Barrientos, M. J., and, Bernales, S., (2009) Role of dopamine in the physiology of T-cells and dendritic cells. J. Neuroimmunol. 216, 8-19.
7. Sarkar, C., Basu, B., Chakroborty, D., Dasgupta, P. S., and, Basu, S., (2010) The immunoregulatory role of dopamine: an update. Brain Behav. Immun. 24, 525-528.
8. McGeer, P. L., and, McGeer, E. G., (2004) Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat. Disord. 10 (Suppl 1), S3-S7.
9. Fasano, M., Alberio, T., and, Lopiano, L., (2008) Peripheral biomarkers of Parkinson's disease as early reporters of central neurodegeneration. Biomark. Med. 2, 465-478.
10. Blandini, F., Bazzini, E., Marino, F., Saporiti, F., Armentero, M. T., et al. (2009) Calcium homeostasis is dysregulated in parkinsonian patients with L -DOPA-induced dyskinesias. Clin. Neuropharmacol. 32, 133-139.
11. Alberio, T., Anchieri, C., Piacentini, L., Gentile, G., Simmaco, M., et al. (2011) Proteomic characterization of Jurkat T leukemic cells after dopamine stimulation: a model of circulating dopamine-sensitive cells. Biochimie 93, 892-898.
12. Alberio, T., and, Fasano, M., (2011) Proteomics in Parkinson's disease: an unbiased approach towards peripheral biomarkers and new therapies. J. Biotechnol. 156, 325-337.
13. Ostrowski, J., and, Wyrwicz, L. S., (2009) Integrating genomics, proteomics and bioinformatics in translational studies of molecular medicine. Expert Rev. Mol. Diagn. 9, 623-630.
14. Caudle, W. M., Bammler, T. K., Lin, Y., Pan, S., and, Zhang, J., (2010) Using 'omics' to define pathogenesis and biomarkers of Parkinson's disease. Expert Rev. Neurother. 10, 925-942.
15. Jankovic, J., (2008) Parkinson's disease: clinical features and diagnosis. J. Neurol. Neurosurg. Psychiatry 79, 368-376.
16. McDonald, J. H., (2009) Handbook of Biological Statistics, 2nd edn. Sparky House Publishing, Baltimore, MD.
17. R Development Core Team (2009) R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna.
18. Alberio, T., Bossi, A. M., Milli, A., Parma, E., Gariboldi, M. B., et al. (2010) Proteomic analysis of dopamine and α-synuclein interplay in a cellular model of Parkinson's disease pathogenesis. FEBS J. 277, 4909-4919.
19. Oli, R. G., Fazeli, G., Kuhn, W., Walitza, S., Gerlach, M., et al. (2010) No increased chromosomal damage in L -DOPA-treated patients with Parkinson's disease: a pilot study. J. Neural. Transm. 117, 737-746.
20. Fanciulli, A., Misasi, R., Campanelli, D., Buttarelli, F. R., and, Pontieri, F. R., (2011) Dopaminergic drug-induced modulation of the expression of the dopamine transporter in peripheral blood lymphocytes in Parkinson's disease. Pharmacol. Rep. 63, 1056-1060.
21. Valastro, B., Dekundy, A., Krogh, M., Lundblad, M., James, P., et al. (2007) Proteomic analysis of striatal proteins in the rat model of L -DOPA-induced dyskinesia. J. Neurochem. 102, 1395-1409.
22. Alberio, T., Lopiano, L., and, Fasano, M., (2012) Cellular models to investigate biochemical pathways in Parkinson's disease. FEBS J. 279, 1146-1155.
23. Petrak, J., Ivanek, R., Toman, O., Cmejla, R., Cmejlova, J., et al. (2008) Déjà vu in proteomics. A hit parade of repeatedly identified differentially expressed proteins. Proteomics 8, 1744-1749.
24. Lupi, A., Tenni, R., Rossi, A., Cetta, G., and, Forlino, A., (2008) Human prolidase and prolidase deficiency: an overview on the characterization of the enzyme involved in proline recycling and on the effects of its mutations. Amino Acids 35, 739-752.
25. Chiravuri, M., and, Huber, B. T., (2000) Aminodipeptidase inhibitor-induced cell death in quiescent lymphocytes: a review. Apoptosis 5, 319-322.
26. Manevich, Y., and, Fisher, A. B., (2005) Peroxiredoxin 6, a 1-Cys peroxiredoxin, functions in antioxidant defense and lung phospholipid metabolism. Free Radic. Biol. Med. 38, 1422-1432.
27. (2) exposure on peroxiredoxin expression in human lymphocytes from young and old individuals. J. Nutr. Biochem. 23, 741-751.
28. Beaulieu, J. M., and, Gainetdinov, R. R., (2011) The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol. Rev. 63, 182-217.
29. Tansey, M. G., and, Goldberg, M. S., (2010) Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol. Dis. 37, 510-518.